New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
08:06 EDTSNYGenzymeís Lemtrada approved in Brazil for MS treatment
Genzyme, a Sanofi company, announced that Brazilís national health surveillance agency, ANVISA, has approved Lemtrada for the treatment of patients with relapsing forms of multiple sclerosis. The approval in Brazil follows the recent approvals of Lemtrada in Mexico, Canada, Australia and the European Union. Lemtrada is currently not approved in the U.S. The Lemtrada clinical development program included two randomized Phase III studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a in patients with RRMS who had active disease and were either new to treatment or who had relapsed while on prior therapy. In CARE-MS I, Lemtrada was more effective than interferon beta-1a at reducing annualized relapse rates. In CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada vs. interferon beta-1a. The most common side effects of Lemtrada are infusion associated reactions, infections, lymphopenia and leukopenia. Autoimmune conditions and serious infections can occur in patients receiving Lemtrada.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
12:25 EDTSNYRegeneron price target lowered to $443 from $607 at Piper Jaffray
Subscribe for More Information
08:08 EDTSNYSanofi sees FY16 business EPS to be broadly stable at CER
Subscribe for More Information
05:28 EDTSNYSanofi reports Q4 business EPS down 5.8% to EUR 1.31
Subscribe for More Information
February 8, 2016
06:28 EDTSNYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 2, 2016
11:09 EDTSNYSanofi plans to cut 600 jobs in France over three years, Bloomberg reports
Subscribe for More Information
07:24 EDTSNYSanofi, Merck mulling exiting vaccine JV, Bloomberg reports
Subscribe for More Information
05:19 EDTSNYSanofi Pasteur launches R&D project targeting prevention of Zika virus infection
Subscribe for More Information
January 29, 2016
13:38 EDTSNYAmgen wins right to allege willful infringement in Praluent suit, Markman says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use